NOXXON Successfully Completes Patient Recruitment in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy
Expansion study planned upon definition of recommended dose to gather additional data BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth…